WeVote
Log In

Bill

Bill

HR 7895

PBM Kickback Prohibition Act

119th Congress Introduced by Rick Allen

Bill prohibits kickback payments to pharmacy benefit managers under ERISA to reduce hidden prescription drug supply chain costs and increase pricing transparency.

Reported (Amended) by the Committee on Education and Workforce. H. Rept. 119-729.
0
WeVote Research Nonpartisan
Bill Summary · HR 7895

Legislative bill overview

HR 7895 proposes to amend ERISA's Section 408 to explicitly prohibit kickbacks paid to pharmacy benefit managers (PBMs). The bill targets financial arrangements between drug manufacturers, pharmacies, and PBMs that currently operate in legal gray areas. It aims to increase transparency and reduce hidden payments within the prescription drug supply chain.

Why is this important

PBMs act as intermediaries controlling drug formularies and negotiating prices for employer health plans and insurers. Kickback arrangements can inflate drug costs for consumers and employers while benefiting PBMs, manufacturers, and pharmacies—ultimately raising insurance premiums and out-of-pocket costs. Clarifying ERISA's prohibition could reduce these hidden incentives and lower overall prescription drug spending.

Potential points of contention

  • Definition precision: The bill must clearly define what constitutes a "kickback" versus legitimate rebates, discounts, or service fees that currently drive PBM business models
  • Industry opposition: PBMs, manufacturers, and pharmacy chains may argue the prohibition disrupts efficient negotiation mechanisms and reduces competition incentives
  • Enforcement challenges: Determining liability and enforcing prohibitions across complex multi-party supply chains will require robust regulatory infrastructure and clear penalties

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.